Surgical Glue Market by Product Type (Biological Adhesive, Synthetic Adhesive), Formulation (Liquid, Patch, Spray), Application, End User - Global Forecast 2025-2032
Description
The Surgical Glue Market was valued at USD 2.31 billion in 2024 and is projected to grow to USD 2.44 billion in 2025, with a CAGR of 6.00%, reaching USD 3.69 billion by 2032.
How material innovations, regulatory evolution, and clinical demand are reshaping the role of surgical adhesives across modern operative care pathways
The surgical glue ecosystem has matured from niche adjuncts to essential tools across an expanding spectrum of operative procedures, driven by clinical demand for faster hemostasis, reduced infection risk, and improved tissue approximation. Innovations in polymer chemistry and biologics have broadened the range of adhesive modalities that surgeons and perioperative teams can deploy, while advances in delivery systems have enhanced precision and ease of use in constrained anatomical spaces. Interdisciplinary research bridging materials science, bioengineering, and clinical practice continues to refine adhesive performance characteristics such as tensile strength, biocompatibility, and resorption profiles.
As the broader healthcare environment emphasizes value-based care, surgical adhesives are increasingly evaluated not only for clinical efficacy but for their capacity to shorten operative times, minimize complications, and enable minimally invasive approaches. Concurrently, regulatory pathways have evolved to better accommodate combination products and novel biomaterials, prompting manufacturers to invest in robust clinical evidence and post-market surveillance. These convergent trends are redefining how hospitals, clinics, and ambulatory surgical centers select and integrate adhesive solutions into standard protocols, and they underscore the need for strategic alignment between product development, clinical adoption, and reimbursement pathways.
Converging technology advances and care delivery shifts that are driving rapid evolution in surgical adhesive performance, adoption, and supply chain resilience
The landscape of surgical adhesives is undergoing transformative shifts as the industry balances technological breakthroughs with changing care delivery models. On the technology front, synthesis and formulation advancements have yielded adhesives that offer tailored degradation rates, enhanced hemostatic properties, and improved adhesion on moist or dynamic tissues. These properties expand clinical applicability into high-mobility environments such as cardiovascular anastomoses and orthopedic reconstructions, where mechanical stability and biological integration are simultaneously required. Innovations in delivery mechanisms have also lowered the barrier to adoption by enabling consistent dosing, targeted placement, and compatibility with minimally invasive instruments.
Simultaneously, the delivery of surgical care is decentralizing from traditional inpatient operating rooms to ambulatory surgical centers and specialized outpatient clinics, prompting manufacturers to rethink packaging, training, and sterilization workflows. Procurement priorities reflect this shift, favoring products that simplify inventory management and reduce perioperative variability. In parallel, payer expectations and hospital value committees increasingly demand evidence of cost-effectiveness and real-world outcomes, driving more rigorous post-market data collection and collaboration between manufacturers and clinical partners. Lastly, global supply chain resilience has become a strategic imperative, encouraging diversification of raw material sourcing and investment in flexible manufacturing capacity to mitigate disruption risks.
How tariffs implemented in 2025 are reshaping sourcing strategies, manufacturing footprints, and procurement priorities across the surgical adhesive value chain
Recent tariff actions implemented in the United States have introduced a new layer of complexity for suppliers, manufacturers, and health systems that rely on global inputs for surgical adhesives. Tariffs on specific chemical precursors, medical device components, and finished goods can alter cost structures across the value chain, prompting sourcing reviews and contract renegotiations. Manufacturers facing higher import duties have started to evaluate nearshoring options, dual-sourcing strategies, and selective local manufacturing to protect margin and ensure uninterrupted supply to clinical customers. These changes have also affected logistics planning and inventory policies, with stakeholders increasing buffer stock and adjusting lead times to offset tariff-induced volatility.
Clinicians and procurement officers have responded by placing greater emphasis on product total cost of ownership rather than unit price alone, recognizing that supply interruptions or variability in product availability can have downstream clinical and financial consequences. In some cases, tariff pressures have accelerated consolidation among suppliers, as scale becomes a competitive advantage for absorbing additional duties while maintaining price stability for institutional buyers. At the regulatory interface, companies are reassessing their compliance exposure when shifting manufacturing footprints, including registration responsibilities and inspection requirements. Overall, the tariffs introduced in 2025 have intensified strategic planning across sourcing, manufacturing, and contract management functions, encouraging more integrated approaches to risk mitigation and supplier partnership models.
Deep segmentation insights that link material classes, delivery formats, clinical indications, and care settings to actionable product and commercialization strategies
Insightful segmentation reveals nuanced pathways for product development and commercialization across distinct material classes, formulations, clinical applications, and care settings. When viewed through the lens of product type, the market separates into biological adhesives and synthetic adhesives, with biological options including albumin-based systems and fibrin sealants that emphasize biocompatibility and native tissue integration, while synthetic alternatives such as cyanoacrylate and polyethylene glycol hydrogel focus on rapid bonding, tunable degradation, and controlled mechanical properties. These material differences inform formulation choices and dictate which clinical niches an adhesive can address effectively.
Formulation modalities further differentiate product performance and user experience. Liquid systems are subdivided into dual component and single component chemistries, where dual component formulations typically provide controlled curing kinetics and surgeon-directed activation, whereas single component liquids offer simpler handling and broader intraoperative utility. Patch-based formats include natural and synthetic substrates that deliver localized reinforcement without relying on adhesive runoff, and spray delivery comes in aerosol spray and jet spray variants that serve distinct needs for surface coverage and depth of penetration. Clinical applications sketch another layer of specificity: cardiovascular surgery involves complex use cases such as heart valve replacement and vascular repair that demand adhesives with high burst strength and hemocompatibility; dental procedures require materials engineered for oral environment resilience; general surgery spans abdominal and thoracic procedures where adhesion to wet tissues and prevention of leakage are paramount; ophthalmic surgery necessitates ultra-fine, minimally inflammatory formulations; and orthopedic surgery targets bone fixation and joint repair where mechanical load-bearing and osteointegration matter.
End-user contexts determine procurement dynamics and adoption cadence. Ambulatory surgical centers, which may be hospital owned or independent, prioritize streamlined inventory and ease of use; clinics, whether outpatient or specialty, require cost-effective, versatile products that integrate with limited storage and staffing; and hospitals, encompassing private and public institutions, value robust clinical evidence, economies of scale in supply contracts, and compatibility with sterilization and quality systems. The intersection of product type, formulation, application, and end-user environment thus creates a matrix of opportunity and constraint that manufacturers must navigate when positioning new adhesives, designing clinical trials, and structuring commercial engagement strategies.
Regional dynamics and healthcare system differences that determine commercial priorities, regulatory tactics, and adoption pathways for surgical adhesives
Regional dynamics exert strong influence over product development priorities, regulatory strategy, and commercial execution. In the Americas, clinical adoption trends emphasize minimally invasive procedures and rapid hemostasis, and payers are increasingly attentive to value demonstrations that link adhesive use to shorter hospital stays and fewer complications. This region also prioritizes compliance with rigorous regulatory standards and well-defined post-market surveillance, encouraging manufacturers to invest in extensive clinical programs and local registration capabilities.
Across Europe, the Middle East and Africa, regulatory harmonization and cross-border procurement create both opportunities and complexity for suppliers. Diverse reimbursement environments and varying hospital procurement rules drive demand for adaptable pricing strategies and evidence packages that translate across healthcare systems. Manufacturers operating here often pursue regional partnerships to navigate fragmented distribution channels and to tailor training programs that address heterogeneous surgical practices.
In the Asia-Pacific region, rapid expansion of surgical capacity, rising investment in specialty care centers, and strong interest in domestic manufacturing create fertile ground for both international and local players. Policymakers in several jurisdictions support medical device localization and skills development, which has prompted some vendors to establish regional production and regulatory footholds. Across all regions, local clinical practice patterns, reimbursement frameworks, and supply chain realities shape adoption curves and determine which product attributes resonate most strongly with clinicians and procurement stakeholders.
Competitive and partnership dynamics that reward integrated technology portfolios, robust clinical validation, and resilient manufacturing strategies for adhesive manufacturers
Competitive dynamics in the surgical adhesive space are characterized by a blend of technology-led differentiation and execution-focused commercial strategy. Leading players typically combine deep materials expertise with clinical trial experience and multi-channel distribution to reach diverse end users. Partnerships with hospital systems, academic surgical centers, and specialty clinics enable product validation and early adoption, while collaborations with contract manufacturers and specialty chemical suppliers support scale-up and cost competitiveness. Firms that invest in training programs and hands-on surgeon education tend to accelerate uptake, as real-world familiarity often translates directly into preference and formulary inclusion.
Mergers, acquisitions, and licensing agreements continue to shape the competitive field by assembling complementary portfolios of biologics, delivery systems, and adjunct technologies such as hemostatic agents or sealant patches. Companies that balance R&D investment with pragmatic attention to regulatory timing and reimbursement positioning maintain advantage, as the pathway from development to hospital procurement requires coordinated evidence generation and stakeholder engagement. Furthermore, firms that proactively address supply chain resilience and transparency earn trust among large hospital customers, where procurement committees increasingly scrutinize supplier continuity plans and quality documentation. Innovation in adjacent areas-such as novel adhesive chemistries, smart delivery devices, and combination products that integrate diagnostic signals-also creates new avenues for differentiation and long-term value capture.
Practical strategic moves for manufacturers, purchasers, and clinicians to secure supply resilience, evidence leadership, and faster adoption of next-generation surgical adhesives
Leaders in product development, procurement, and clinical practice can take concrete steps to convert market complexity into strategic advantage. Manufacturers should prioritize modular platform designs that allow rapid customization across material types and formulations, enabling faster responses to specific clinical needs and regulatory requirements. Investing in scalable manufacturing and regional production nodes will mitigate exposure to tariff-induced cost increases and logistical bottlenecks, while strategic partnerships with contract manufacturers can provide flexible capacity without heavy capital outlay. In parallel, firms must develop comprehensive clinical evidence plans that include comparative effectiveness studies, health economics analyses, and real-world evidence collection to address payer and hospital demands for demonstrable value.
Health system purchasers should adopt procurement frameworks that value total cost of care and supply continuity, refining contractual terms to incentivize supplier transparency and rapid response capabilities. Clinical leaders can facilitate adoption by participating in multicenter registries and targeted training initiatives that reduce variability in application technique and outcomes. Across stakeholders, strengthening cross-functional collaboration between R&D, regulatory, clinical affairs, and commercial teams will accelerate alignment on product positioning and market entry strategies. Finally, all players should maintain vigilant scenario planning for policy shifts, tariff changes, and raw material constraints, embedding contingency plans into sourcing and inventory policies to preserve patient access and operational stability.
A comprehensive mixed-methods methodology combining primary interviews, documentary analysis, and triangulation to produce validated segmentation and regional insights
The research approach integrates qualitative and quantitative methods to ensure robust, triangulated insights. Primary research included structured interviews with a broad set of stakeholders spanning surgeons, procurement officers, regulatory specialists, and manufacturing executives, providing firsthand perspectives on clinical preferences, operational constraints, and strategic priorities. Secondary research encompassed peer-reviewed literature, regulatory filings, clinical trial registries, patent landscapes, and publicly available company documentation to map technological trajectories, approval histories, and product claims. Data synthesis relied on cross-validation between primary input and documentary evidence, with discrepancies resolved through targeted follow-up conversations and sensitivity analyses.
Segmentation and regional analyses were developed by mapping product attributes to clinical use cases and end-user needs, then validating those mappings with subject-matter experts to ensure practical relevance. Supply chain and tariff implications were assessed using trade flow data and industry interviews to capture both near-term disruptions and longer-term strategic adjustments. The methodology consciously applied transparency and reproducibility principles, documenting data sources, interview protocols, and analytical assumptions, while acknowledging limitations such as evolving regulatory changes and the confidential nature of some proprietary commercial agreements.
Synthesis of clinical, regulatory, and commercial imperatives that determine which surgical adhesive technologies will achieve durable adoption in evolving healthcare systems
Surgical adhesives occupy a strategic junction between materials science and clinical practice, with broad potential to improve procedural efficiency and patient outcomes when matched thoughtfully to clinical needs. The evolving regulatory environment, shifting care delivery models, and external pressures such as tariffs and supply chain disruption compel stakeholders to prioritize flexibility in sourcing, clarity in evidence generation, and alignment across clinical and procurement teams. Manufacturers that can demonstrate both product performance and system-level value will stand best positioned to gain durable adoption across hospitals, ambulatory centers, and clinics.
Moving forward, successful commercialization will hinge on the ability to integrate technical innovation with pragmatic execution: scalable manufacturing, tailored clinical evidence, and agile distribution networks. By anticipating policy shifts and investing in partnerships that expand clinical validation and local manufacturing capacity, stakeholders can sustain momentum and deliver adhesives that meet the nuanced demands of contemporary surgical care.
Please Note: PDF & Excel + Online Access - 1 Year
How material innovations, regulatory evolution, and clinical demand are reshaping the role of surgical adhesives across modern operative care pathways
The surgical glue ecosystem has matured from niche adjuncts to essential tools across an expanding spectrum of operative procedures, driven by clinical demand for faster hemostasis, reduced infection risk, and improved tissue approximation. Innovations in polymer chemistry and biologics have broadened the range of adhesive modalities that surgeons and perioperative teams can deploy, while advances in delivery systems have enhanced precision and ease of use in constrained anatomical spaces. Interdisciplinary research bridging materials science, bioengineering, and clinical practice continues to refine adhesive performance characteristics such as tensile strength, biocompatibility, and resorption profiles.
As the broader healthcare environment emphasizes value-based care, surgical adhesives are increasingly evaluated not only for clinical efficacy but for their capacity to shorten operative times, minimize complications, and enable minimally invasive approaches. Concurrently, regulatory pathways have evolved to better accommodate combination products and novel biomaterials, prompting manufacturers to invest in robust clinical evidence and post-market surveillance. These convergent trends are redefining how hospitals, clinics, and ambulatory surgical centers select and integrate adhesive solutions into standard protocols, and they underscore the need for strategic alignment between product development, clinical adoption, and reimbursement pathways.
Converging technology advances and care delivery shifts that are driving rapid evolution in surgical adhesive performance, adoption, and supply chain resilience
The landscape of surgical adhesives is undergoing transformative shifts as the industry balances technological breakthroughs with changing care delivery models. On the technology front, synthesis and formulation advancements have yielded adhesives that offer tailored degradation rates, enhanced hemostatic properties, and improved adhesion on moist or dynamic tissues. These properties expand clinical applicability into high-mobility environments such as cardiovascular anastomoses and orthopedic reconstructions, where mechanical stability and biological integration are simultaneously required. Innovations in delivery mechanisms have also lowered the barrier to adoption by enabling consistent dosing, targeted placement, and compatibility with minimally invasive instruments.
Simultaneously, the delivery of surgical care is decentralizing from traditional inpatient operating rooms to ambulatory surgical centers and specialized outpatient clinics, prompting manufacturers to rethink packaging, training, and sterilization workflows. Procurement priorities reflect this shift, favoring products that simplify inventory management and reduce perioperative variability. In parallel, payer expectations and hospital value committees increasingly demand evidence of cost-effectiveness and real-world outcomes, driving more rigorous post-market data collection and collaboration between manufacturers and clinical partners. Lastly, global supply chain resilience has become a strategic imperative, encouraging diversification of raw material sourcing and investment in flexible manufacturing capacity to mitigate disruption risks.
How tariffs implemented in 2025 are reshaping sourcing strategies, manufacturing footprints, and procurement priorities across the surgical adhesive value chain
Recent tariff actions implemented in the United States have introduced a new layer of complexity for suppliers, manufacturers, and health systems that rely on global inputs for surgical adhesives. Tariffs on specific chemical precursors, medical device components, and finished goods can alter cost structures across the value chain, prompting sourcing reviews and contract renegotiations. Manufacturers facing higher import duties have started to evaluate nearshoring options, dual-sourcing strategies, and selective local manufacturing to protect margin and ensure uninterrupted supply to clinical customers. These changes have also affected logistics planning and inventory policies, with stakeholders increasing buffer stock and adjusting lead times to offset tariff-induced volatility.
Clinicians and procurement officers have responded by placing greater emphasis on product total cost of ownership rather than unit price alone, recognizing that supply interruptions or variability in product availability can have downstream clinical and financial consequences. In some cases, tariff pressures have accelerated consolidation among suppliers, as scale becomes a competitive advantage for absorbing additional duties while maintaining price stability for institutional buyers. At the regulatory interface, companies are reassessing their compliance exposure when shifting manufacturing footprints, including registration responsibilities and inspection requirements. Overall, the tariffs introduced in 2025 have intensified strategic planning across sourcing, manufacturing, and contract management functions, encouraging more integrated approaches to risk mitigation and supplier partnership models.
Deep segmentation insights that link material classes, delivery formats, clinical indications, and care settings to actionable product and commercialization strategies
Insightful segmentation reveals nuanced pathways for product development and commercialization across distinct material classes, formulations, clinical applications, and care settings. When viewed through the lens of product type, the market separates into biological adhesives and synthetic adhesives, with biological options including albumin-based systems and fibrin sealants that emphasize biocompatibility and native tissue integration, while synthetic alternatives such as cyanoacrylate and polyethylene glycol hydrogel focus on rapid bonding, tunable degradation, and controlled mechanical properties. These material differences inform formulation choices and dictate which clinical niches an adhesive can address effectively.
Formulation modalities further differentiate product performance and user experience. Liquid systems are subdivided into dual component and single component chemistries, where dual component formulations typically provide controlled curing kinetics and surgeon-directed activation, whereas single component liquids offer simpler handling and broader intraoperative utility. Patch-based formats include natural and synthetic substrates that deliver localized reinforcement without relying on adhesive runoff, and spray delivery comes in aerosol spray and jet spray variants that serve distinct needs for surface coverage and depth of penetration. Clinical applications sketch another layer of specificity: cardiovascular surgery involves complex use cases such as heart valve replacement and vascular repair that demand adhesives with high burst strength and hemocompatibility; dental procedures require materials engineered for oral environment resilience; general surgery spans abdominal and thoracic procedures where adhesion to wet tissues and prevention of leakage are paramount; ophthalmic surgery necessitates ultra-fine, minimally inflammatory formulations; and orthopedic surgery targets bone fixation and joint repair where mechanical load-bearing and osteointegration matter.
End-user contexts determine procurement dynamics and adoption cadence. Ambulatory surgical centers, which may be hospital owned or independent, prioritize streamlined inventory and ease of use; clinics, whether outpatient or specialty, require cost-effective, versatile products that integrate with limited storage and staffing; and hospitals, encompassing private and public institutions, value robust clinical evidence, economies of scale in supply contracts, and compatibility with sterilization and quality systems. The intersection of product type, formulation, application, and end-user environment thus creates a matrix of opportunity and constraint that manufacturers must navigate when positioning new adhesives, designing clinical trials, and structuring commercial engagement strategies.
Regional dynamics and healthcare system differences that determine commercial priorities, regulatory tactics, and adoption pathways for surgical adhesives
Regional dynamics exert strong influence over product development priorities, regulatory strategy, and commercial execution. In the Americas, clinical adoption trends emphasize minimally invasive procedures and rapid hemostasis, and payers are increasingly attentive to value demonstrations that link adhesive use to shorter hospital stays and fewer complications. This region also prioritizes compliance with rigorous regulatory standards and well-defined post-market surveillance, encouraging manufacturers to invest in extensive clinical programs and local registration capabilities.
Across Europe, the Middle East and Africa, regulatory harmonization and cross-border procurement create both opportunities and complexity for suppliers. Diverse reimbursement environments and varying hospital procurement rules drive demand for adaptable pricing strategies and evidence packages that translate across healthcare systems. Manufacturers operating here often pursue regional partnerships to navigate fragmented distribution channels and to tailor training programs that address heterogeneous surgical practices.
In the Asia-Pacific region, rapid expansion of surgical capacity, rising investment in specialty care centers, and strong interest in domestic manufacturing create fertile ground for both international and local players. Policymakers in several jurisdictions support medical device localization and skills development, which has prompted some vendors to establish regional production and regulatory footholds. Across all regions, local clinical practice patterns, reimbursement frameworks, and supply chain realities shape adoption curves and determine which product attributes resonate most strongly with clinicians and procurement stakeholders.
Competitive and partnership dynamics that reward integrated technology portfolios, robust clinical validation, and resilient manufacturing strategies for adhesive manufacturers
Competitive dynamics in the surgical adhesive space are characterized by a blend of technology-led differentiation and execution-focused commercial strategy. Leading players typically combine deep materials expertise with clinical trial experience and multi-channel distribution to reach diverse end users. Partnerships with hospital systems, academic surgical centers, and specialty clinics enable product validation and early adoption, while collaborations with contract manufacturers and specialty chemical suppliers support scale-up and cost competitiveness. Firms that invest in training programs and hands-on surgeon education tend to accelerate uptake, as real-world familiarity often translates directly into preference and formulary inclusion.
Mergers, acquisitions, and licensing agreements continue to shape the competitive field by assembling complementary portfolios of biologics, delivery systems, and adjunct technologies such as hemostatic agents or sealant patches. Companies that balance R&D investment with pragmatic attention to regulatory timing and reimbursement positioning maintain advantage, as the pathway from development to hospital procurement requires coordinated evidence generation and stakeholder engagement. Furthermore, firms that proactively address supply chain resilience and transparency earn trust among large hospital customers, where procurement committees increasingly scrutinize supplier continuity plans and quality documentation. Innovation in adjacent areas-such as novel adhesive chemistries, smart delivery devices, and combination products that integrate diagnostic signals-also creates new avenues for differentiation and long-term value capture.
Practical strategic moves for manufacturers, purchasers, and clinicians to secure supply resilience, evidence leadership, and faster adoption of next-generation surgical adhesives
Leaders in product development, procurement, and clinical practice can take concrete steps to convert market complexity into strategic advantage. Manufacturers should prioritize modular platform designs that allow rapid customization across material types and formulations, enabling faster responses to specific clinical needs and regulatory requirements. Investing in scalable manufacturing and regional production nodes will mitigate exposure to tariff-induced cost increases and logistical bottlenecks, while strategic partnerships with contract manufacturers can provide flexible capacity without heavy capital outlay. In parallel, firms must develop comprehensive clinical evidence plans that include comparative effectiveness studies, health economics analyses, and real-world evidence collection to address payer and hospital demands for demonstrable value.
Health system purchasers should adopt procurement frameworks that value total cost of care and supply continuity, refining contractual terms to incentivize supplier transparency and rapid response capabilities. Clinical leaders can facilitate adoption by participating in multicenter registries and targeted training initiatives that reduce variability in application technique and outcomes. Across stakeholders, strengthening cross-functional collaboration between R&D, regulatory, clinical affairs, and commercial teams will accelerate alignment on product positioning and market entry strategies. Finally, all players should maintain vigilant scenario planning for policy shifts, tariff changes, and raw material constraints, embedding contingency plans into sourcing and inventory policies to preserve patient access and operational stability.
A comprehensive mixed-methods methodology combining primary interviews, documentary analysis, and triangulation to produce validated segmentation and regional insights
The research approach integrates qualitative and quantitative methods to ensure robust, triangulated insights. Primary research included structured interviews with a broad set of stakeholders spanning surgeons, procurement officers, regulatory specialists, and manufacturing executives, providing firsthand perspectives on clinical preferences, operational constraints, and strategic priorities. Secondary research encompassed peer-reviewed literature, regulatory filings, clinical trial registries, patent landscapes, and publicly available company documentation to map technological trajectories, approval histories, and product claims. Data synthesis relied on cross-validation between primary input and documentary evidence, with discrepancies resolved through targeted follow-up conversations and sensitivity analyses.
Segmentation and regional analyses were developed by mapping product attributes to clinical use cases and end-user needs, then validating those mappings with subject-matter experts to ensure practical relevance. Supply chain and tariff implications were assessed using trade flow data and industry interviews to capture both near-term disruptions and longer-term strategic adjustments. The methodology consciously applied transparency and reproducibility principles, documenting data sources, interview protocols, and analytical assumptions, while acknowledging limitations such as evolving regulatory changes and the confidential nature of some proprietary commercial agreements.
Synthesis of clinical, regulatory, and commercial imperatives that determine which surgical adhesive technologies will achieve durable adoption in evolving healthcare systems
Surgical adhesives occupy a strategic junction between materials science and clinical practice, with broad potential to improve procedural efficiency and patient outcomes when matched thoughtfully to clinical needs. The evolving regulatory environment, shifting care delivery models, and external pressures such as tariffs and supply chain disruption compel stakeholders to prioritize flexibility in sourcing, clarity in evidence generation, and alignment across clinical and procurement teams. Manufacturers that can demonstrate both product performance and system-level value will stand best positioned to gain durable adoption across hospitals, ambulatory centers, and clinics.
Moving forward, successful commercialization will hinge on the ability to integrate technical innovation with pragmatic execution: scalable manufacturing, tailored clinical evidence, and agile distribution networks. By anticipating policy shifts and investing in partnerships that expand clinical validation and local manufacturing capacity, stakeholders can sustain momentum and deliver adhesives that meet the nuanced demands of contemporary surgical care.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of cyanoacrylate-based tissue adhesives for faster wound closure in outpatient settings
- 5.2. Technological integration of nanoparticles to enhance antimicrobial properties in surgical glues
- 5.3. Development of biodegradable and hemostatic surgical adhesives to reduce post-surgical complications
- 5.4. Growing focus on UV-curable surgical glues for precise tissue bonding in minimally invasive procedures
- 5.5. Strategic partnerships between pharmaceutical companies and medical device manufacturers to innovate surgical adhesives
- 5.6. Increasing regulatory approvals for advanced sealants driving market expansion in emerging economies
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Surgical Glue Market, by Product Type
- 8.1. Biological Adhesive
- 8.1.1. Albumin
- 8.1.2. Fibrin Sealant
- 8.2. Synthetic Adhesive
- 8.2.1. Cyanoacrylate
- 8.2.2. Polyethylene Glycol Hydrogel
- 9. Surgical Glue Market, by Formulation
- 9.1. Liquid
- 9.1.1. Dual Component
- 9.1.2. Single Component
- 9.2. Patch
- 9.2.1. Natural Patch
- 9.2.2. Synthetic Patch
- 9.3. Spray
- 9.3.1. Aerosol Spray
- 9.3.2. Jet Spray
- 10. Surgical Glue Market, by Application
- 10.1. Cardiovascular Surgery
- 10.1.1. Heart Valve Replacement
- 10.1.2. Vascular Repair
- 10.2. Dental
- 10.3. General Surgery
- 10.3.1. Abdominal Procedures
- 10.3.2. Thoracic Procedures
- 10.4. Ophthalmic Surgery
- 10.5. Orthopedic Surgery
- 10.5.1. Bone Fixation
- 10.5.2. Joint Repair
- 11. Surgical Glue Market, by End User
- 11.1. Ambulatory Surgical Center
- 11.1.1. Hospital Owned ASC
- 11.1.2. Independent ASC
- 11.2. Clinic
- 11.2.1. Outpatient Clinic
- 11.2.2. Specialty Clinic
- 11.3. Hospital
- 11.3.1. Private Hospital
- 11.3.2. Public Hospital
- 12. Surgical Glue Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Surgical Glue Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Surgical Glue Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Ethicon, Inc.
- 15.3.2. Medtronic plc
- 15.3.3. B. Braun Melsungen AG
- 15.3.4. 3M Company
- 15.3.5. Baxter International Inc
- 15.3.6. Smith & Nephew plc
- 15.3.7. CryoLife, Inc.
- 15.3.8. Integra LifeSciences Corporation
- 15.3.9. Adhezion Biomedical, LLC
- 15.3.10. Cohera Medical, Inc.
- 15.3.11. Becton Dickinson & Co.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
